\babel@toc {english}{}\relax 
\contentsline {part}{I\hspace {1em}Notes}{10}{part.1}%
\contentsline {chapter}{\numberline {1}Introduction}{11}{chapter.1}%
\contentsline {section}{\numberline {1.1}Genetics and genomics}{11}{section.1.1}%
\contentsline {subsection}{\numberline {1.1.1}Genetics}{11}{subsection.1.1.1}%
\contentsline {subsection}{\numberline {1.1.2}Genomics}{11}{subsection.1.1.2}%
\contentsline {subsection}{\numberline {1.1.3}Differences between genetics and genomics}{11}{subsection.1.1.3}%
\contentsline {subsection}{\numberline {1.1.4}The role of computational biology}{12}{subsection.1.1.4}%
\contentsline {section}{\numberline {1.2}Basis of human genomics}{12}{section.1.2}%
\contentsline {subsection}{\numberline {1.2.1}Single nucleotide polymorphisms}{12}{subsection.1.2.1}%
\contentsline {subsection}{\numberline {1.2.2}Copy number variants}{12}{subsection.1.2.2}%
\contentsline {subsection}{\numberline {1.2.3}Inherited variants}{12}{subsection.1.2.3}%
\contentsline {subsubsection}{\numberline {1.2.3.1}Penetrance}{13}{subsubsection.1.2.3.1}%
\contentsline {subsubsection}{\numberline {1.2.3.2}Allele frequency}{13}{subsubsection.1.2.3.2}%
\contentsline {subsubsection}{\numberline {1.2.3.3}Differences in Genetic Make-Up, an example}{13}{subsubsection.1.2.3.3}%
\contentsline {subsection}{\numberline {1.2.4}Somatic Variants}{14}{subsection.1.2.4}%
\contentsline {subsubsection}{\numberline {1.2.4.1}Classification}{14}{subsubsection.1.2.4.1}%
\contentsline {subsubsection}{\numberline {1.2.4.2}Types of acquired DNA aberrations}{14}{subsubsection.1.2.4.2}%
\contentsline {paragraph}{\numberline {1.2.4.2.1}Translocation}{14}{paragraph.1.2.4.2.1}%
\contentsline {paragraph}{\numberline {1.2.4.2.2}Inversion}{14}{paragraph.1.2.4.2.2}%
\contentsline {paragraph}{\numberline {1.2.4.2.3}Copy number changes}{15}{paragraph.1.2.4.2.3}%
\contentsline {paragraph}{\numberline {1.2.4.2.4}Chromoplexy}{15}{paragraph.1.2.4.2.4}%
\contentsline {section}{\numberline {1.3}Experimental techniques to detect variants/aberrations}{15}{section.1.3}%
\contentsline {subsection}{\numberline {1.3.1}Karyotyping}{15}{subsection.1.3.1}%
\contentsline {subsection}{\numberline {1.3.2}Sequence capture for cancer genomics}{15}{subsection.1.3.2}%
\contentsline {subsubsection}{\numberline {1.3.2.1}Reference}{15}{subsubsection.1.3.2.1}%
\contentsline {subsubsection}{\numberline {1.3.2.2}Deepness}{16}{subsubsection.1.3.2.2}%
\contentsline {subsubsection}{\numberline {1.3.2.3}Single End (SE) and Paired End (PE) reads}{16}{subsubsection.1.3.2.3}%
\contentsline {paragraph}{\numberline {1.3.2.3.1}Single end sequencing}{16}{paragraph.1.3.2.3.1}%
\contentsline {paragraph}{\numberline {1.3.2.3.2}Paired end sequencing}{16}{paragraph.1.3.2.3.2}%
\contentsline {paragraph}{\numberline {1.3.2.3.3}Ability of paired end sequencing to detect genomic aberrations}{16}{paragraph.1.3.2.3.3}%
\contentsline {chapter}{\numberline {2}Coverage}{17}{chapter.2}%
\contentsline {section}{\numberline {2.1}Computing coverage}{17}{section.2.1}%
\contentsline {subsection}{\numberline {2.1.1}Local coverage}{17}{subsection.2.1.1}%
\contentsline {subsection}{\numberline {2.1.2}Allelic fraction}{17}{subsection.2.1.2}%
\contentsline {subsection}{\numberline {2.1.3}NGS global coverage}{17}{subsection.2.1.3}%
\contentsline {section}{\numberline {2.2}Mapping in NGS}{17}{section.2.2}%
\contentsline {subsection}{\numberline {2.2.1}Sequence coverage}{18}{subsection.2.2.1}%
\contentsline {subsection}{\numberline {2.2.2}Physical coverage}{18}{subsection.2.2.2}%
\contentsline {section}{\numberline {2.3}Tuning coverage}{18}{section.2.3}%
\contentsline {subsection}{\numberline {2.3.1}SNP detection}{18}{subsection.2.3.1}%
\contentsline {subsection}{\numberline {2.3.2}Subclonal events}{18}{subsection.2.3.2}%
\contentsline {subsection}{\numberline {2.3.3}Amplicon-based approaches}{19}{subsection.2.3.3}%
\contentsline {subsubsection}{\numberline {2.3.3.1}Heterozygous deletion of PTEN}{19}{subsubsection.2.3.3.1}%
\contentsline {subsubsection}{\numberline {2.3.3.2}Homozygous deletion of PTEN}{19}{subsubsection.2.3.3.2}%
\contentsline {subsubsection}{\numberline {2.3.3.3}Amplification of AR}{19}{subsubsection.2.3.3.3}%
\contentsline {subsection}{\numberline {2.3.4}NGS-based approaches}{20}{subsection.2.3.4}%
\contentsline {subsubsection}{\numberline {2.3.4.1}Advantages over amplicon-based approaches}{20}{subsubsection.2.3.4.1}%
\contentsline {subsubsection}{\numberline {2.3.4.2}Problems of NGS-based approaches}{20}{subsubsection.2.3.4.2}%
\contentsline {section}{\numberline {2.4}Databases for NGS analysis}{20}{section.2.4}%
\contentsline {subsection}{\numberline {2.4.1}Genome reference consortium}{20}{subsection.2.4.1}%
\contentsline {subsection}{\numberline {2.4.2}USCS genome browser}{20}{subsection.2.4.2}%
\contentsline {chapter}{\numberline {3}Genetic Fingerprinting}{21}{chapter.3}%
\contentsline {section}{\numberline {3.1}Introduction}{21}{section.3.1}%
\contentsline {subsection}{\numberline {3.1.1}Fields of interest}{21}{subsection.3.1.1}%
\contentsline {subsection}{\numberline {3.1.2}Variants used for genetic testing}{21}{subsection.3.1.2}%
\contentsline {subsubsection}{\numberline {3.1.2.1}CNVs}{21}{subsubsection.3.1.2.1}%
\contentsline {subsubsection}{\numberline {3.1.2.2}SNPs}{22}{subsubsection.3.1.2.2}%
\contentsline {section}{\numberline {3.2}SNPs features}{22}{section.3.2}%
\contentsline {subsection}{\numberline {3.2.1}Hardy-Weinberg equilibrium}{22}{subsection.3.2.1}%
\contentsline {subsection}{\numberline {3.2.2}Minor allele frequency}{22}{subsection.3.2.2}%
\contentsline {subsubsection}{\numberline {3.2.2.1}Optimal MAF values for genetic fingerprinting}{22}{subsubsection.3.2.2.1}%
\contentsline {subsection}{\numberline {3.2.3}Haplotype blocks}{23}{subsection.3.2.3}%
\contentsline {subsubsection}{\numberline {3.2.3.1}Linkage disequilibrium}{23}{subsubsection.3.2.3.1}%
\contentsline {subsubsection}{\numberline {3.2.3.2}Tag SNPs}{23}{subsubsection.3.2.3.2}%
\contentsline {subsection}{\numberline {3.2.4}Other SNP features}{24}{subsection.3.2.4}%
\contentsline {subsection}{\numberline {3.2.5}Number of SNPs to select when performing a genetic test}{24}{subsection.3.2.5}%
\contentsline {subsubsection}{\numberline {3.2.5.1}Experimental mismatches - Genotype call error rate}{24}{subsubsection.3.2.5.1}%
\contentsline {paragraph}{\numberline {3.2.5.1.1}An example on the effect of experimental mismatches}{25}{figure.caption.12}%
\contentsline {subsubsection}{\numberline {3.2.5.2}Biological mismatches}{25}{subsubsection.3.2.5.2}%
\contentsline {paragraph}{\numberline {3.2.5.2.1}Loss of Heterozygosity (LOH)}{25}{paragraph.3.2.5.2.1}%
\contentsline {paragraph}{\numberline {3.2.5.2.2}Gain Of Heterozygosity (GOH)}{25}{paragraph.3.2.5.2.2}%
\contentsline {paragraph}{\numberline {3.2.5.2.3}Double Mutation (DM)}{25}{paragraph.3.2.5.2.3}%
\contentsline {paragraph}{\numberline {3.2.5.2.4}Modelling biological mismatches}{25}{paragraph.3.2.5.2.4}%
\contentsline {subsection}{\numberline {3.2.6}Project regarding SNPs}{26}{subsection.3.2.6}%
\contentsline {subsubsection}{\numberline {3.2.6.1}dbSNPs}{26}{subsubsection.3.2.6.1}%
\contentsline {subsubsection}{\numberline {3.2.6.2}HapMap3}{26}{subsubsection.3.2.6.2}%
\contentsline {section}{\numberline {3.3}Genetic distance}{26}{section.3.3}%
\contentsline {subsection}{\numberline {3.3.1}Measuring distance}{26}{subsection.3.3.1}%
\contentsline {subsubsection}{\numberline {3.3.1.1}Expected distance}{28}{subsubsection.3.3.1.1}%
\contentsline {subsubsection}{\numberline {3.3.1.2}Identifying a sample origin from RAP samples}{29}{subsubsection.3.3.1.2}%
\contentsline {subsection}{\numberline {3.3.2}Distance changes with different numbers of SNPs}{30}{subsection.3.3.2}%
\contentsline {section}{\numberline {3.4}Building a SNP-based genetic test}{30}{section.3.4}%
\contentsline {subsection}{\numberline {3.4.1}Pipeline}{30}{subsection.3.4.1}%
\contentsline {subsection}{\numberline {3.4.2}Implementation of a probabilistic test to identify samples}{31}{subsection.3.4.2}%
\contentsline {subsubsection}{\numberline {3.4.2.1}Classification}{31}{subsubsection.3.4.2.1}%
\contentsline {subsection}{\numberline {3.4.3}Some examples of genetic tests}{32}{subsection.3.4.3}%
\contentsline {subsubsection}{\numberline {3.4.3.1}Investigating cell line passages}{32}{subsubsection.3.4.3.1}%
\contentsline {subsubsection}{\numberline {3.4.3.2}Investigating individual relatedness}{32}{subsubsection.3.4.3.2}%
\contentsline {subsection}{\numberline {3.4.4}Genetic structure of the human population}{33}{subsection.3.4.4}%
\contentsline {subsubsection}{\numberline {3.4.4.1}Genes mirror geography in Europe}{34}{subsubsection.3.4.4.1}%
\contentsline {chapter}{\numberline {4}IGV (Integrative Genomics Viewer)}{36}{chapter.4}%
\contentsline {section}{\numberline {4.1}IGV characteristics}{36}{section.4.1}%
\contentsline {subsection}{\numberline {4.1.1}Introduction}{36}{subsection.4.1.1}%
\contentsline {subsection}{\numberline {4.1.2}Main uses of IGV}{36}{subsection.4.1.2}%
\contentsline {subsubsection}{\numberline {4.1.2.1}RNA sequence analysis}{37}{subsubsection.4.1.2.1}%
\contentsline {subsubsection}{\numberline {4.1.2.2}Variant discovery}{38}{subsubsection.4.1.2.2}%
\contentsline {subsection}{\numberline {4.1.3}Operations}{38}{subsection.4.1.3}%
\contentsline {subsection}{\numberline {4.1.4}Tiles}{39}{subsection.4.1.4}%
\contentsline {subsubsection}{\numberline {4.1.4.1}Pixel resolution error}{39}{subsubsection.4.1.4.1}%
\contentsline {subsubsection}{\numberline {4.1.4.2}Data displayed at different resolutions}{40}{subsubsection.4.1.4.2}%
\contentsline {subsection}{\numberline {4.1.5}IGVTools}{40}{subsection.4.1.5}%
\contentsline {subsection}{\numberline {4.1.6}Session files}{40}{subsection.4.1.6}%
\contentsline {section}{\numberline {4.2}Interpreting pair orientations}{41}{section.4.2}%
\contentsline {subsection}{\numberline {4.2.1}Element to consider when interpreting pair orientations}{41}{subsection.4.2.1}%
\contentsline {subsection}{\numberline {4.2.2}Inversion}{41}{subsection.4.2.2}%
\contentsline {subsection}{\numberline {4.2.3}Tandem duplication}{42}{subsection.4.2.3}%
\contentsline {subsection}{\numberline {4.2.4}Inverted duplication}{42}{subsection.4.2.4}%
\contentsline {subsection}{\numberline {4.2.5}Deletion}{43}{subsection.4.2.5}%
\contentsline {section}{\numberline {4.3}Uncovering genetic aberrations - some examples}{43}{section.4.3}%
\contentsline {subsection}{\numberline {4.3.1}First example}{43}{subsection.4.3.1}%
\contentsline {subsection}{\numberline {4.3.2}Second example}{43}{subsection.4.3.2}%
\contentsline {subsection}{\numberline {4.3.3}Third example}{44}{subsection.4.3.3}%
\contentsline {chapter}{\numberline {5}Tumor Evolution Studies via NGS data}{46}{chapter.5}%
\contentsline {section}{\numberline {5.1}Tumour evolution}{46}{section.5.1}%
\contentsline {subsection}{\numberline {5.1.1}Introduction}{46}{subsection.5.1.1}%
\contentsline {subsubsection}{\numberline {5.1.1.1}Typical traits of cancer}{46}{subsubsection.5.1.1.1}%
\contentsline {subsubsection}{\numberline {5.1.1.2}Tumour boards}{46}{subsubsection.5.1.1.2}%
\contentsline {subsection}{\numberline {5.1.2}Heterogeneity}{47}{subsection.5.1.2}%
\contentsline {subsubsection}{\numberline {5.1.2.1}Temporal heterogeneity}{47}{subsubsection.5.1.2.1}%
\contentsline {subsubsection}{\numberline {5.1.2.2}Spatial heterogeneity}{47}{subsubsection.5.1.2.2}%
\contentsline {subsection}{\numberline {5.1.3}Type of evolutions}{47}{subsection.5.1.3}%
\contentsline {subsubsection}{\numberline {5.1.3.1}Linear evolution}{48}{subsubsection.5.1.3.1}%
\contentsline {subsubsection}{\numberline {5.1.3.2}Branched evolution}{48}{subsubsection.5.1.3.2}%
\contentsline {subsection}{\numberline {5.1.4}Treatment resistance}{48}{subsection.5.1.4}%
\contentsline {subsubsection}{\numberline {5.1.4.1}Primary resistance}{49}{subsubsection.5.1.4.1}%
\contentsline {subsubsection}{\numberline {5.1.4.2}Acquired resistance}{49}{subsubsection.5.1.4.2}%
\contentsline {section}{\numberline {5.2}Using NGS data to uncover tumour evolution}{49}{section.5.2}%
\contentsline {subsection}{\numberline {5.2.1}Introduction}{49}{subsection.5.2.1}%
\contentsline {subsection}{\numberline {5.2.2}Admixture}{50}{subsection.5.2.2}%
\contentsline {subsection}{\numberline {5.2.3}Informative SNPs}{50}{subsection.5.2.3}%
\contentsline {subsection}{\numberline {5.2.4}Beta value}{51}{subsection.5.2.4}%
\contentsline {subsubsection}{\numberline {5.2.4.1}Computing beta}{52}{subsubsection.5.2.4.1}%
\contentsline {subsubsection}{\numberline {5.2.4.2}Effect of coverage on beta}{53}{subsubsection.5.2.4.2}%
\contentsline {subsection}{\numberline {5.2.5}Estimates of global and local admixture}{53}{subsection.5.2.5}%
\contentsline {subsubsection}{\numberline {5.2.5.1}Estimates of DNA admixture}{54}{subsubsection.5.2.5.1}%
\contentsline {subsection}{\numberline {5.2.6}PR-2741 - an example}{55}{subsection.5.2.6}%
\contentsline {chapter}{\numberline {6}Tumor evolution studies: copy number based methods}{57}{chapter.6}%
\contentsline {section}{\numberline {6.1}Analysis of clonality}{57}{section.6.1}%
\contentsline {subsection}{\numberline {6.1.1}Informative SNPs}{57}{subsection.6.1.1}%
\contentsline {subsection}{\numberline {6.1.2}Log2 ratio}{57}{subsection.6.1.2}%
\contentsline {subsection}{\numberline {6.1.3}Beta value}{58}{subsection.6.1.3}%
\contentsline {subsection}{\numberline {6.1.4}Cluster analysis in the beta-log2 ratio space}{58}{subsection.6.1.4}%
\contentsline {section}{\numberline {6.2}Evolution maps}{59}{section.6.2}%
\contentsline {subsection}{\numberline {6.2.1}Introduction}{59}{subsection.6.2.1}%
\contentsline {subsection}{\numberline {6.2.2}Building an evolution map}{59}{subsection.6.2.2}%
\contentsline {subsection}{\numberline {6.2.3}A toy example}{59}{subsection.6.2.3}%
\contentsline {subsection}{\numberline {6.2.4}A real world data example}{61}{subsection.6.2.4}%
\contentsline {subsubsection}{\numberline {6.2.4.1}Limitations}{61}{subsubsection.6.2.4.1}%
\contentsline {subsection}{\numberline {6.2.5}Pathway-based evolutionary maps}{61}{subsection.6.2.5}%
\contentsline {subsubsection}{\numberline {6.2.5.1}Timing}{62}{subsubsection.6.2.5.1}%
\contentsline {subsubsection}{\numberline {6.2.5.2}Treatment}{62}{subsubsection.6.2.5.2}%
\contentsline {section}{\numberline {6.3}Ploidy and purity corrections}{62}{section.6.3}%
\contentsline {subsection}{\numberline {6.3.1}Introduction}{62}{subsection.6.3.1}%
\contentsline {subsection}{\numberline {6.3.2}A melanoma example}{63}{subsection.6.3.2}%
\contentsline {subsubsection}{\numberline {6.3.2.1}Ploidy correction}{63}{subsubsection.6.3.2.1}%
\contentsline {subsubsection}{\numberline {6.3.2.2}Purity correction}{64}{subsubsection.6.3.2.2}%
\contentsline {subsection}{\numberline {6.3.3}A melanoma example considering more samples}{64}{subsection.6.3.3}%
\contentsline {subsection}{\numberline {6.3.4}An example with TGCA data}{65}{subsection.6.3.4}%
\contentsline {subsubsection}{\numberline {6.3.4.1}Ploidy correction}{65}{subsubsection.6.3.4.1}%
\contentsline {section}{\numberline {6.4}Allele-specific analysis}{66}{section.6.4}%
\contentsline {subsection}{\numberline {6.4.1}Introduction}{66}{subsection.6.4.1}%
\contentsline {subsection}{\numberline {6.4.2}An example}{67}{subsection.6.4.2}%
\contentsline {subsubsection}{\numberline {6.4.2.1}Changes of copy number for specific alleles}{68}{subsubsection.6.4.2.1}%
\contentsline {subsubsection}{\numberline {6.4.2.2}Copy number neutral events}{68}{subsubsection.6.4.2.2}%
\contentsline {subsection}{\numberline {6.4.3}A case study}{69}{subsection.6.4.3}%
\contentsline {subsubsection}{\numberline {6.4.3.1}Primary site}{70}{subsubsection.6.4.3.1}%
\contentsline {subsubsection}{\numberline {6.4.3.2}Metastasis}{70}{subsubsection.6.4.3.2}%
\contentsline {section}{\numberline {6.5}Longitudinal plasma profiling}{71}{section.6.5}%
\contentsline {subsection}{\numberline {6.5.1}An example}{71}{subsection.6.5.1}%
\contentsline {subsection}{\numberline {6.5.2}Tracking evolution}{72}{subsection.6.5.2}%
\contentsline {chapter}{\numberline {7}Tumor evolution studies: SNVs-based methods}{73}{chapter.7}%
\contentsline {section}{\numberline {7.1}Introduction}{73}{section.7.1}%
\contentsline {subsection}{\numberline {7.1.1}Copy-number neutral tumours}{73}{subsection.7.1.1}%
\contentsline {subsection}{\numberline {7.1.2}Different methods for tumour assessment}{74}{subsection.7.1.2}%
\contentsline {subsection}{\numberline {7.1.3}Rationale of SNV based methods}{74}{subsection.7.1.3}%
\contentsline {subsection}{\numberline {7.1.4}Advantages and limitations of SNVs based methods}{74}{subsection.7.1.4}%
\contentsline {subsection}{\numberline {7.1.5}Reference mapping bias}{75}{subsection.7.1.5}%
\contentsline {section}{\numberline {7.2}TPES - tumour purity estimation from SNVs}{75}{section.7.2}%
\contentsline {subsection}{\numberline {7.2.1}Introduction}{75}{subsection.7.2.1}%
\contentsline {subsection}{\numberline {7.2.2}SNV identification}{75}{subsection.7.2.2}%
\contentsline {subsubsection}{\numberline {7.2.2.1}Selection of copy-number neutral segments}{76}{subsubsection.7.2.2.1}%
\contentsline {subsubsection}{\numberline {7.2.2.2}Allelic fraction}{76}{subsubsection.7.2.2.2}%
\contentsline {subsubsection}{\numberline {7.2.2.3}Identification of putative clonal SNVs}{76}{subsubsection.7.2.2.3}%
\contentsline {subsection}{\numberline {7.2.3}Purity estimation}{76}{subsection.7.2.3}%
\contentsline {subsection}{\numberline {7.2.4}Minimal number of SNV for tumour identification}{76}{subsection.7.2.4}%
\contentsline {subsection}{\numberline {7.2.5}Comparison with other tumour callers}{77}{subsection.7.2.5}%
\contentsline {chapter}{\numberline {8}Liquid biopsies in oncology}{78}{chapter.8}%
\contentsline {section}{\numberline {8.1}Introduction}{78}{section.8.1}%
\contentsline {subsection}{\numberline {8.1.1}Tracking tumour progression}{78}{subsection.8.1.1}%
\contentsline {subsection}{\numberline {8.1.2}Differences between tissue and liquid biopsies}{78}{subsection.8.1.2}%
\contentsline {subsubsection}{\numberline {8.1.2.1}Liquid biopsies allow to perform a number of analysis}{79}{subsubsection.8.1.2.1}%
\contentsline {subsubsection}{\numberline {8.1.2.2}Material availability}{79}{subsubsection.8.1.2.2}%
\contentsline {subsubsection}{\numberline {8.1.2.3}Tumour content}{79}{subsubsection.8.1.2.3}%
\contentsline {subsubsection}{\numberline {8.1.2.4}Assessment of tumour ploidy}{79}{subsubsection.8.1.2.4}%
\contentsline {subsection}{\numberline {8.1.3}Application-dependent requirements}{80}{subsection.8.1.3}%
\contentsline {subsubsection}{\numberline {8.1.3.1}Early tumour, MRD and recurrence detection}{80}{subsubsection.8.1.3.1}%
\contentsline {subsubsection}{\numberline {8.1.3.2}Analysis of tumour dynamics, treatment response and analysis of the mechanisms of resistance}{80}{subsubsection.8.1.3.2}%
\contentsline {subsubsection}{\numberline {8.1.3.3}Single biomarker assessment}{80}{subsubsection.8.1.3.3}%
\contentsline {subsection}{\numberline {8.1.4}Whole-genome and targeted sequencing}{80}{subsection.8.1.4}%
\contentsline {subsection}{\numberline {8.1.5}Challenges in tracking tumour evolution with liquid biopsies}{81}{subsection.8.1.5}%
\contentsline {subsubsection}{\numberline {8.1.5.1}An example of similarity between two plasma samples between two different tumours}{81}{subsubsection.8.1.5.1}%
\contentsline {section}{\numberline {8.2}Interpretation of cell free DNA data}{81}{section.8.2}%
\contentsline {subsection}{\numberline {8.2.1}Introduction}{81}{subsection.8.2.1}%
\contentsline {subsection}{\numberline {8.2.2}Normalization}{81}{subsection.8.2.2}%
\contentsline {subsection}{\numberline {8.2.3}Quantity of input material}{82}{subsection.8.2.3}%
\contentsline {subsection}{\numberline {8.2.4}SNVs detection}{83}{subsection.8.2.4}%
\contentsline {subsubsection}{\numberline {8.2.4.1}Technical problems}{83}{subsubsection.8.2.4.1}%
\contentsline {subsubsection}{\numberline {8.2.4.2}Biological problems}{84}{subsubsection.8.2.4.2}%
\contentsline {subsection}{\numberline {8.2.5}Two case studies}{84}{subsection.8.2.5}%
\contentsline {subsubsection}{\numberline {8.2.5.1}Signal distribution in prostate cancer}{84}{subsubsection.8.2.5.1}%
\contentsline {subsubsection}{\numberline {8.2.5.2}Non-AR driven castration resistance prostate cancer}{84}{subsubsection.8.2.5.2}%
\contentsline {chapter}{\numberline {9}Extracellular vesicles}{86}{chapter.9}%
\contentsline {section}{\numberline {9.1}Introduction}{86}{section.9.1}%
\contentsline {subsection}{\numberline {9.1.1}Definition}{86}{subsection.9.1.1}%
\contentsline {subsection}{\numberline {9.1.2}Compartments of extracellular vesicles}{86}{subsection.9.1.2}%
\contentsline {subsubsection}{\numberline {9.1.2.1}Outside layer}{86}{subsubsection.9.1.2.1}%
\contentsline {subsubsection}{\numberline {9.1.2.2}Content}{86}{subsubsection.9.1.2.2}%
\contentsline {subsubsection}{\numberline {9.1.2.3}Membrane proteins}{87}{subsubsection.9.1.2.3}%
\contentsline {subsection}{\numberline {9.1.3}Characterization of extracellular vesicles}{87}{subsection.9.1.3}%
\contentsline {subsubsection}{\numberline {9.1.3.1}Size}{87}{subsubsection.9.1.3.1}%
\contentsline {subsubsection}{\numberline {9.1.3.2}Origin}{87}{subsubsection.9.1.3.2}%
\contentsline {paragraph}{\numberline {9.1.3.2.1}Process of origin of exosomes}{87}{paragraph.9.1.3.2.1}%
\contentsline {subsubsection}{\numberline {9.1.3.3}Content}{88}{subsubsection.9.1.3.3}%
\contentsline {paragraph}{\numberline {9.1.3.3.1}Exosomes and microvesicles}{88}{paragraph.9.1.3.3.1}%
\contentsline {paragraph}{\numberline {9.1.3.3.2}Apoptotic bodies}{88}{paragraph.9.1.3.3.2}%
\contentsline {paragraph}{\numberline {9.1.3.3.3}Exosomes}{88}{paragraph.9.1.3.3.3}%
\contentsline {subsection}{\numberline {9.1.4}Functions of extracellular vesicles}{89}{subsection.9.1.4}%
\contentsline {subsubsection}{\numberline {9.1.4.1}Functions of extracellular vesicles in cancer}{89}{subsubsection.9.1.4.1}%
\contentsline {section}{\numberline {9.2}Tumour studies through extracellular vesicles analysis}{89}{section.9.2}%
\contentsline {subsection}{\numberline {9.2.1}Introduction}{89}{subsection.9.2.1}%
\contentsline {subsection}{\numberline {9.2.2}Breast cancer - an example}{90}{subsection.9.2.2}%
\contentsline {subsection}{\numberline {9.2.3}Tracking tumour signal in serial samples}{90}{subsection.9.2.3}%
\contentsline {subsection}{\numberline {9.2.4}Extracellular vesicles isolation methods}{90}{subsection.9.2.4}%
\contentsline {subsection}{\numberline {9.2.5}Challenges in studying tumour evolution through extracellular vesicles}{91}{subsection.9.2.5}%
\contentsline {subsection}{\numberline {9.2.6}Deconvolution}{91}{subsection.9.2.6}%
\contentsline {subsubsection}{\numberline {9.2.6.1}Supervised deconvolution}{91}{subsubsection.9.2.6.1}%
\contentsline {subsubsection}{\numberline {9.2.6.2}Unsupervised deconvolution}{92}{subsubsection.9.2.6.2}%
\contentsline {subsection}{\numberline {9.2.7}Conclusion}{92}{subsection.9.2.7}%
\contentsline {chapter}{\numberline {10}Epigenetic profiling of cell-free DNA}{93}{chapter.10}%
\contentsline {section}{\numberline {10.1}Introduction}{93}{section.10.1}%
\contentsline {subsection}{\numberline {10.1.1}Epigenetic}{93}{subsection.10.1.1}%
\contentsline {subsubsection}{\numberline {10.1.1.1}Epigenetic modifications}{93}{subsubsection.10.1.1.1}%
\contentsline {subsubsection}{\numberline {10.1.1.2}Epigenetic plasticity}{93}{subsubsection.10.1.1.2}%
\contentsline {subsubsection}{\numberline {10.1.1.3}Epigenetic deregulation}{93}{subsubsection.10.1.1.3}%
\contentsline {subsection}{\numberline {10.1.2}DNA methylation}{93}{subsection.10.1.2}%
\contentsline {subsubsection}{\numberline {10.1.2.1}CpG islands}{94}{subsubsection.10.1.2.1}%
\contentsline {subsubsection}{\numberline {10.1.2.2}Cancer tissues}{94}{subsubsection.10.1.2.2}%
\contentsline {subsubsection}{\numberline {10.1.2.3}Landscape of regulation}{94}{subsubsection.10.1.2.3}%
\contentsline {subsubsection}{\numberline {10.1.2.4}DNA methylation markers}{95}{subsubsection.10.1.2.4}%
\contentsline {subsection}{\numberline {10.1.3}Measuring DNA methylation}{95}{subsection.10.1.3}%
\contentsline {subsubsection}{\numberline {10.1.3.1}Bisulphite conversion}{95}{subsubsection.10.1.3.1}%
\contentsline {subsubsection}{\numberline {10.1.3.2}Sequencing and alignment}{95}{subsubsection.10.1.3.2}%
\contentsline {subsubsection}{\numberline {10.1.3.3}Computing beta values}{95}{subsubsection.10.1.3.3}%
\contentsline {subsubsection}{\numberline {10.1.3.4}Single read analysis}{96}{subsubsection.10.1.3.4}%
\contentsline {section}{\numberline {10.2}DNA methylation based liquid biopsy}{96}{section.10.2}%
\contentsline {subsection}{\numberline {10.2.1}Introduction}{96}{subsection.10.2.1}%
\contentsline {subsection}{\numberline {10.2.2}Comparison with genomics-based liquid biopsies}{96}{subsection.10.2.2}%
\contentsline {subsection}{\numberline {10.2.3}Workflow}{97}{subsection.10.2.3}%
\contentsline {subsection}{\numberline {10.2.4}CCGA study}{97}{subsection.10.2.4}%
\contentsline {subsubsection}{\numberline {10.2.4.1}Obtaining methylation profiles}{97}{subsubsection.10.2.4.1}%
\contentsline {subsubsection}{\numberline {10.2.4.2}Results}{98}{subsubsection.10.2.4.2}%
\contentsline {subsection}{\numberline {10.2.5}Deconvolution approach}{98}{subsection.10.2.5}%
\contentsline {subsubsection}{\numberline {10.2.5.1}Considering liquid biopsies}{98}{subsubsection.10.2.5.1}%
\contentsline {subsubsection}{\numberline {10.2.5.2}High-quality reference atlases}{98}{subsubsection.10.2.5.2}%
\contentsline {subsection}{\numberline {10.2.6}Targeted panel approaches for tumour content estimation}{98}{subsection.10.2.6}%
\contentsline {part}{II\hspace {1em}Laboratory}{99}{part.2}%
\contentsline {chapter}{\numberline {11}Relevant file's formats}{100}{chapter.11}%
\contentsline {section}{\numberline {11.1}FASTA format}{100}{section.11.1}%
\contentsline {subsection}{\numberline {11.1.1}Components}{100}{subsection.11.1.1}%
\contentsline {subsection}{\numberline {11.1.2}Alphabet}{100}{subsection.11.1.2}%
\contentsline {subsection}{\numberline {11.1.3}DNA sequence quality}{100}{subsection.11.1.3}%
\contentsline {section}{\numberline {11.2}FASTQ format}{101}{section.11.2}%
\contentsline {subsection}{\numberline {11.2.1}Data compression}{101}{subsection.11.2.1}%
\contentsline {section}{\numberline {11.3}SAM and BAM formats}{101}{section.11.3}%
\contentsline {subsection}{\numberline {11.3.1}SAM files}{101}{subsection.11.3.1}%
\contentsline {subsubsection}{\numberline {11.3.1.1}COmposition}{101}{subsubsection.11.3.1.1}%
\contentsline {subsection}{\numberline {11.3.2}BAM files}{101}{subsection.11.3.2}%
\contentsline {subsection}{\numberline {11.3.3}Operation with SAM and BAM files}{101}{subsection.11.3.3}%
\contentsline {subsubsection}{\numberline {11.3.3.1}Converting from SAM to BAM}{102}{subsubsection.11.3.3.1}%
\contentsline {subsubsection}{\numberline {11.3.3.2}Filtering}{102}{subsubsection.11.3.3.2}%
\contentsline {subsubsection}{\numberline {11.3.3.3}Explore statistics}{102}{subsubsection.11.3.3.3}%
\contentsline {subsubsection}{\numberline {11.3.3.4}Mpileup}{102}{subsubsection.11.3.3.4}%
\contentsline {chapter}{\numberline {12}Data pre-processing}{103}{chapter.12}%
\contentsline {section}{\numberline {12.1}Realignment}{103}{section.12.1}%
\contentsline {subsection}{\numberline {12.1.1}Introduction}{103}{subsection.12.1.1}%
\contentsline {subsection}{\numberline {12.1.2}An example}{103}{subsection.12.1.2}%
\contentsline {subsection}{\numberline {12.1.3}Objective of realignment}{103}{subsection.12.1.3}%
\contentsline {subsection}{\numberline {12.1.4}GATK}{103}{subsection.12.1.4}%
\contentsline {subsection}{\numberline {12.1.5}Protocol}{104}{subsection.12.1.5}%
\contentsline {subsection}{\numberline {12.1.6}Realignment results}{104}{subsection.12.1.6}%
\contentsline {section}{\numberline {12.2}Recalibration}{104}{section.12.2}%
\contentsline {subsection}{\numberline {12.2.1}Introduction}{104}{subsection.12.2.1}%
\contentsline {subsubsection}{\numberline {12.2.1.1}Dealing with systematic errors}{104}{subsubsection.12.2.1.1}%
\contentsline {subsection}{\numberline {12.2.2}Computing empirical qualities}{104}{subsection.12.2.2}%
\contentsline {subsubsection}{\numberline {12.2.2.1}Base quality score recalibration}{105}{subsubsection.12.2.2.1}%
\contentsline {subsection}{\numberline {12.2.3}Protocol}{105}{subsection.12.2.3}%
\contentsline {section}{\numberline {12.3}Marking duplicates}{105}{section.12.3}%
\contentsline {subsection}{\numberline {12.3.1}Introduction}{105}{subsection.12.3.1}%
\contentsline {subsection}{\numberline {12.3.2}Identification of duplicates}{105}{subsection.12.3.2}%
\contentsline {subsubsection}{\numberline {12.3.2.1}Consideration on Borrow-Wheeler aligner}{106}{subsubsection.12.3.2.1}%
\contentsline {subsection}{\numberline {12.3.3}Protocol}{106}{subsection.12.3.3}%
\contentsline {chapter}{\numberline {13}Variant calling}{107}{chapter.13}%
\contentsline {section}{\numberline {13.1}Introduction}{107}{section.13.1}%
\contentsline {subsection}{\numberline {13.1.1}Objective of variant calling}{107}{subsection.13.1.1}%
\contentsline {subsection}{\numberline {13.1.2}Bayes' rule for variant calling}{107}{subsection.13.1.2}%
\contentsline {section}{\numberline {13.2}Likelihood estimation for variant calling}{107}{section.13.2}%
\contentsline {subsection}{\numberline {13.2.1}Available tools}{108}{subsection.13.2.1}%
\contentsline {section}{\numberline {13.3}VCF files}{108}{section.13.3}%
\contentsline {subsection}{\numberline {13.3.1}Composition}{108}{subsection.13.3.1}%
\contentsline {subsection}{\numberline {13.3.2}Vcftools}{108}{subsection.13.3.2}%
\contentsline {section}{\numberline {13.4}A variant calling protocol}{109}{section.13.4}%
\contentsline {chapter}{\numberline {14}Variant annotation}{110}{chapter.14}%
\contentsline {section}{\numberline {14.1}Introduction}{110}{section.14.1}%
\contentsline {subsection}{\numberline {14.1.1}Annotation databases}{110}{subsection.14.1.1}%
\contentsline {subsubsection}{\numberline {14.1.1.1}Genomic data repositories}{110}{subsubsection.14.1.1.1}%
\contentsline {subsubsection}{\numberline {14.1.1.2}Variant-disease databases}{110}{subsubsection.14.1.1.2}%
\contentsline {subsubsection}{\numberline {14.1.1.3}Conservation and pathogenicity prediction databases}{110}{subsubsection.14.1.1.3}%
\contentsline {section}{\numberline {14.2}SnpEff}{111}{section.14.2}%
\contentsline {subsection}{\numberline {14.2.1}Introduction}{111}{subsection.14.2.1}%
\contentsline {subsection}{\numberline {14.2.2}Set of transcripts}{111}{subsection.14.2.2}%
\contentsline {subsection}{\numberline {14.2.3}Populating the VCF}{111}{subsection.14.2.3}%
\contentsline {subsection}{\numberline {14.2.4}Common annotations}{111}{subsection.14.2.4}%
\contentsline {subsection}{\numberline {14.2.5}SnpSift}{111}{subsection.14.2.5}%
\contentsline {chapter}{\numberline {15}Ancestry}{112}{chapter.15}%
\contentsline {section}{\numberline {15.1}Introduction}{112}{section.15.1}%
\contentsline {subsection}{\numberline {15.1.1}Population stratification}{112}{subsection.15.1.1}%
\contentsline {subsection}{\numberline {15.1.2}Methods}{112}{subsection.15.1.2}%
\contentsline {subsubsection}{\numberline {15.1.2.1}Principal Component analysis based methods}{112}{subsubsection.15.1.2.1}%
\contentsline {subsubsection}{\numberline {15.1.2.2}Model based methods}{112}{subsubsection.15.1.2.2}%
\contentsline {section}{\numberline {15.2}SMARTPCA}{112}{section.15.2}%
\contentsline {subsection}{\numberline {15.2.1}Introduction}{112}{subsection.15.2.1}%
\contentsline {subsection}{\numberline {15.2.2}PED format}{113}{subsection.15.2.2}%
\contentsline {subsection}{\numberline {15.2.3}Output}{113}{subsection.15.2.3}%
\contentsline {section}{\numberline {15.3}fastSTRUCTURE}{113}{section.15.3}%
\contentsline {subsection}{\numberline {15.3.1}Input}{113}{subsection.15.3.1}%
\contentsline {subsection}{\numberline {15.3.2}Output}{113}{subsection.15.3.2}%
\contentsline {section}{\numberline {15.4}EthSEQ}{113}{section.15.4}%
\contentsline {subsection}{\numberline {15.4.1}Introduction}{113}{subsection.15.4.1}%
\contentsline {subsection}{\numberline {15.4.2}Analysing sequencing data}{114}{subsection.15.4.2}%
\contentsline {subsection}{\numberline {15.4.3}Multi step refinement}{114}{subsection.15.4.3}%
\contentsline {subsection}{\numberline {15.4.4}Dealing with ambiguous points}{114}{subsection.15.4.4}%
\contentsline {chapter}{\numberline {16}Somatic variant calling}{115}{chapter.16}%
\contentsline {section}{\numberline {16.1}Introduction}{115}{section.16.1}%
\contentsline {subsection}{\numberline {16.1.1}Genomic alterations}{115}{subsection.16.1.1}%
\contentsline {subsection}{\numberline {16.1.2}Methods}{115}{subsection.16.1.2}%
\contentsline {subsection}{\numberline {16.1.3}Choosing a caller}{116}{subsection.16.1.3}%
\contentsline {subsection}{\numberline {16.1.4}JointSNVMix and VarScan2}{116}{subsection.16.1.4}%
\contentsline {section}{\numberline {16.2}Varscan 2}{116}{section.16.2}%
\contentsline {subsection}{\numberline {16.2.1}Introduction}{116}{subsection.16.2.1}%
\contentsline {subsection}{\numberline {16.2.2}Calling variants}{116}{subsection.16.2.2}%
\contentsline {subsubsection}{\numberline {16.2.2.1}Tumour matches normal}{116}{subsubsection.16.2.2.1}%
\contentsline {subsubsection}{\numberline {16.2.2.2}Tumour does not match normal}{116}{subsubsection.16.2.2.2}%
\contentsline {subsection}{\numberline {16.2.3}Filtering}{117}{subsection.16.2.3}%
\contentsline {chapter}{\numberline {17}Somatic copy number calling}{118}{chapter.17}%
\contentsline {section}{\numberline {17.1}Introduction}{118}{section.17.1}%
\contentsline {subsection}{\numberline {17.1.1}Copy number mutations}{118}{subsection.17.1.1}%
\contentsline {subsection}{\numberline {17.1.2}Effect of CNVs}{118}{subsection.17.1.2}%
\contentsline {section}{\numberline {17.2}Circular binary segmentation}{118}{section.17.2}%
\contentsline {subsection}{\numberline {17.2.1}Introduction}{118}{subsection.17.2.1}%
\contentsline {subsection}{\numberline {17.2.2}Input}{118}{subsection.17.2.2}%
\contentsline {subsection}{\numberline {17.2.3}An example}{118}{subsection.17.2.3}%
\contentsline {subsection}{\numberline {17.2.4}Null hypothesis}{119}{subsection.17.2.4}%
\contentsline {subsection}{\numberline {17.2.5}DNAcopy}{119}{subsection.17.2.5}%
\contentsline {subsection}{\numberline {17.2.6}Changing parameters}{120}{subsection.17.2.6}%
\contentsline {subsection}{\numberline {17.2.7}Visualizing CNVs}{120}{subsection.17.2.7}%
\contentsline {subsubsection}{\numberline {17.2.7.1}IGV}{120}{subsubsection.17.2.7.1}%
\contentsline {subsubsection}{\numberline {17.2.7.2}Histogram}{120}{subsubsection.17.2.7.2}%
\contentsline {subsubsection}{\numberline {17.2.7.3}Browsing a CNV across many individual}{120}{subsubsection.17.2.7.3}%
\contentsline {section}{\numberline {17.3}CNV calling in WES}{120}{section.17.3}%
\contentsline {subsection}{\numberline {17.3.1}Applying CBS}{120}{subsection.17.3.1}%
\contentsline {part}{III\hspace {1em}Papers}{121}{part.3}%
\contentsline {chapter}{\numberline {18}Role of non-coding sequence variants in cancer}{122}{chapter.18}%
\contentsline {section}{\numberline {18.1}Abstract}{122}{section.18.1}%
\contentsline {subsection}{\numberline {18.1.1}Introduction}{122}{subsection.18.1.1}%
\contentsline {section}{\numberline {18.2}Genomic sequence variants}{122}{section.18.2}%
\contentsline {subsection}{\numberline {18.2.1}Categorization of variants}{122}{subsection.18.2.1}%
\contentsline {subsection}{\numberline {18.2.2}Somatic variants}{122}{subsection.18.2.2}%
\contentsline {subsection}{\numberline {18.2.3}Germline variants}{123}{subsection.18.2.3}%
\contentsline {section}{\numberline {18.3}Non-coding element annotation}{123}{section.18.3}%
\contentsline {subsection}{\numberline {18.3.1}Cis regulatory regions}{123}{subsection.18.3.1}%
\contentsline {subsection}{\numberline {18.3.2}Distal regulatory elements}{123}{subsection.18.3.2}%
\contentsline {subsection}{\numberline {18.3.3}RNA-seq}{123}{subsection.18.3.3}%
\contentsline {subsection}{\numberline {18.3.4}Transcribed pseudogenes}{124}{subsection.18.3.4}%
\contentsline {subsection}{\numberline {18.3.5}Evolutionary conservation}{124}{subsection.18.3.5}%
\contentsline {subsection}{\numberline {18.3.6}Conservation among humans}{124}{subsection.18.3.6}%
\contentsline {section}{\numberline {18.4}Roles for somatic variants in cancer}{124}{section.18.4}%
\contentsline {subsection}{\numberline {18.4.1}Gain of TF-binding sites}{125}{subsection.18.4.1}%
\contentsline {subsection}{\numberline {18.4.2}Fusion events due to genomic rearrangements}{125}{subsection.18.4.2}%
\contentsline {subsection}{\numberline {18.4.3}ncRNAs and their binding sites}{125}{subsection.18.4.3}%
\contentsline {subsection}{\numberline {18.4.4}Role of pseudogenes in modulating the expression of a parental gene}{125}{subsection.18.4.4}%
\contentsline {section}{\numberline {18.5}Roles for germline variants in cancer}{125}{section.18.5}%
\contentsline {subsection}{\numberline {18.5.1}Promoter mutations}{125}{subsection.18.5.1}%
\contentsline {subsection}{\numberline {18.5.2}SNPs in enhancers}{126}{subsection.18.5.2}%
\contentsline {subsection}{\numberline {18.5.3}Variants in introns}{126}{subsection.18.5.3}%
\contentsline {subsection}{\numberline {18.5.4}SNPs in ncRNA and their binding sites}{126}{subsection.18.5.4}%
\contentsline {subsection}{\numberline {18.5.5}Others}{126}{subsection.18.5.5}%
\contentsline {subsection}{\numberline {18.5.6}Interplay between germline and somatic variants}{126}{subsection.18.5.6}%
\contentsline {section}{\numberline {18.6}Computational methods for identifying variants}{126}{section.18.6}%
\contentsline {subsection}{\numberline {18.6.1}Analysis of the recurrence of somatic variants}{126}{subsection.18.6.1}%
\contentsline {subsection}{\numberline {18.6.2}Computational identification of non-coding driver}{127}{subsection.18.6.2}%
\contentsline {subsection}{\numberline {18.6.3}Annotation and prioritization of potentially functional non-coding variants}{127}{subsection.18.6.3}%
\contentsline {subsection}{\numberline {18.6.4}Biological networks}{127}{subsection.18.6.4}%
\contentsline {subsection}{\numberline {18.6.5}Conservation}{127}{subsection.18.6.5}%
\contentsline {section}{\numberline {18.7}Experimental approaches for functional validation}{127}{section.18.7}%
\contentsline {subsection}{\numberline {18.7.1}Introducing the sequence variants}{127}{subsection.18.7.1}%
\contentsline {subsection}{\numberline {18.7.2}Evaluating variants' effect}{127}{subsection.18.7.2}%
\contentsline {subsection}{\numberline {18.7.3}High-throughput methods}{127}{subsection.18.7.3}%
\contentsline {subsection}{\numberline {18.7.4}CRE-Seq}{128}{subsection.18.7.4}%
\contentsline {subsection}{\numberline {18.7.5}STARR-Seq}{128}{subsection.18.7.5}%
\contentsline {subsection}{\numberline {18.7.6}Minigene assays}{128}{subsection.18.7.6}%
\contentsline {subsection}{\numberline {18.7.7}Functional screening and validation}{128}{subsection.18.7.7}%
\contentsline {chapter}{\numberline {19}Advances in understanding cancer genomics through second-generation sequencing}{129}{chapter.19}%
\contentsline {section}{\numberline {19.1}Abstract}{129}{section.19.1}%
\contentsline {subsection}{\numberline {19.1.1}Introduction}{129}{subsection.19.1.1}%
\contentsline {section}{\numberline {19.2}Cancer-specific consideration}{129}{section.19.2}%
\contentsline {subsection}{\numberline {19.2.1}Characteristics of cancer samples for genomic analysis}{130}{subsection.19.2.1}%
\contentsline {subsection}{\numberline {19.2.2}Structural variability of cancer genomes}{130}{subsection.19.2.2}%
\contentsline {section}{\numberline {19.3}Experimental approaches}{130}{section.19.3}%
\contentsline {subsection}{\numberline {19.3.1}Whole genome sequencing}{130}{subsection.19.3.1}%
\contentsline {subsection}{\numberline {19.3.2}Exome sequencing}{131}{subsection.19.3.2}%
\contentsline {subsection}{\numberline {19.3.3}Transcriptome sequencing}{131}{subsection.19.3.3}%
\contentsline {section}{\numberline {19.4}Detecting classes of genome alterations}{131}{section.19.4}%
\contentsline {subsection}{\numberline {19.4.1}Somatic nucleotide substitutions and small insertion and deletion mutations}{131}{subsection.19.4.1}%
\contentsline {subsection}{\numberline {19.4.2}Copy number}{131}{subsection.19.4.2}%
\contentsline {subsection}{\numberline {19.4.3}Chromosomal rearrangements}{132}{subsection.19.4.3}%
\contentsline {subsection}{\numberline {19.4.4}Microbe-discovery methods}{132}{subsection.19.4.4}%
\contentsline {section}{\numberline {19.5}Computational issues}{132}{section.19.5}%
\contentsline {subsection}{\numberline {19.5.1}Alignment and assembly}{132}{subsection.19.5.1}%
\contentsline {subsection}{\numberline {19.5.2}Mutations detection}{132}{subsection.19.5.2}%
\contentsline {subsection}{\numberline {19.5.3}Validation of mutation and rearrangement calls}{133}{subsection.19.5.3}%
\contentsline {chapter}{\numberline {20}Tumour heterogeneity and resistance to cancer therapies}{134}{chapter.20}%
\contentsline {section}{\numberline {20.1}Abstract}{134}{section.20.1}%
\contentsline {subsection}{\numberline {20.1.1}Introduction}{134}{subsection.20.1.1}%
\contentsline {section}{\numberline {20.2}Causes of intratumoral heterogeneity}{134}{section.20.2}%
\contentsline {subsection}{\numberline {20.2.1}Genomic instability}{134}{subsection.20.2.1}%
\contentsline {subsection}{\numberline {20.2.2}The clonal evolution and selection hypothesis}{135}{subsection.20.2.2}%
\contentsline {section}{\numberline {20.3}The spectrum of tumour heterogeneity}{135}{section.20.3}%
\contentsline {subsection}{\numberline {20.3.1}Spatial heterogeneity}{135}{subsection.20.3.1}%
\contentsline {subsubsection}{\numberline {20.3.1.1}Heterogeneity at a single disease site}{135}{subsubsection.20.3.1.1}%
\contentsline {subsubsection}{\numberline {20.3.1.2}Comparison of spatially distinct disease sites}{136}{subsubsection.20.3.1.2}%
\contentsline {subsection}{\numberline {20.3.2}Temporal heterogeneity}{136}{subsection.20.3.2}%
\contentsline {subsubsection}{\numberline {20.3.2.1}Genomic complexity might increase with exposure to targeted therapies}{136}{subsubsection.20.3.2.1}%
\contentsline {subsubsection}{\numberline {20.3.2.2}Longitudinal sampling provides insight into temporal heterogeneity}{136}{subsubsection.20.3.2.2}%
\contentsline {subsubsection}{\numberline {20.3.2.3}Residual drug-tolerant cells can foster temporal heterogeneity}{136}{subsubsection.20.3.2.3}%
\contentsline {section}{\numberline {20.4}Non-invasive monitoring of heterogeneity}{137}{section.20.4}%
\contentsline {subsection}{\numberline {20.4.1}Analysis of ctDNA}{137}{subsection.20.4.1}%
\contentsline {section}{\numberline {20.5}Overcoming heterogeneity}{137}{section.20.5}%
\contentsline {chapter}{\numberline {21}Unravelling the clonal hierarchy of somatic genomic aberrations}{139}{chapter.21}%
\contentsline {section}{\numberline {21.1}Introduction}{139}{section.21.1}%
\contentsline {subsection}{\numberline {21.1.1}Abstract}{139}{subsection.21.1.1}%
\contentsline {subsection}{\numberline {21.1.2}Background}{139}{subsection.21.1.2}%
\contentsline {section}{\numberline {21.2}Results}{140}{section.21.2}%
\contentsline {subsection}{\numberline {21.2.1}Clonality assessment of aberrations from sequencing reads}{140}{subsection.21.2.1}%
\contentsline {subsubsection}{\numberline {21.2.1.1}Mono-allelic deletions}{140}{subsubsection.21.2.1.1}%
\contentsline {subsubsection}{\numberline {21.2.1.2}Gain of copy}{140}{subsubsection.21.2.1.2}%
\contentsline {subsubsection}{\numberline {21.2.1.3}Bi-allelic deletions}{140}{subsubsection.21.2.1.3}%
\contentsline {subsubsection}{\numberline {21.2.1.4}Ploidy}{140}{subsubsection.21.2.1.4}%
\contentsline {subsubsection}{\numberline {21.2.1.5}Clonality estimates}{141}{subsubsection.21.2.1.5}%
\contentsline {subsubsection}{\numberline {21.2.1.6}Structural rearrangments}{141}{subsubsection.21.2.1.6}%
\contentsline {subsection}{\numberline {21.2.2}Inferring the order of mutations in a tumour sample}{141}{subsection.21.2.2}%
\contentsline {subsection}{\numberline {21.2.3}In silico and in situ experimental validation}{141}{subsection.21.2.3}%
\contentsline {subsection}{\numberline {21.2.4}Comparative analysis reveals different mechanisms of tumour deregulation}{142}{subsection.21.2.4}%
\contentsline {subsection}{\numberline {21.2.5}Clonal hierarchy of genomic aberrations}{142}{subsection.21.2.5}%
\contentsline {section}{\numberline {21.3}Materials and methods}{142}{section.21.3}%
\contentsline {subsection}{\numberline {21.3.1}CLONET pipeline}{142}{subsection.21.3.1}%
\contentsline {subsection}{\numberline {21.3.2}CLONET on exome and targeted sequencing data}{143}{subsection.21.3.2}%
\contentsline {subsection}{\numberline {21.3.3}Expected distribution of the allelic fraction of a genomic segment}{143}{subsection.21.3.3}%
\contentsline {subsection}{\numberline {21.3.4}Estimated proportion of neutral reads for a genomic segment}{143}{subsection.21.3.4}%
\contentsline {subsection}{\numberline {21.3.5}From neutral to non-aberrant reads}{143}{subsection.21.3.5}%
\contentsline {subsection}{\numberline {21.3.6}From aberrant reads to aberrant cells}{144}{subsection.21.3.6}%
\contentsline {subsection}{\numberline {21.3.7}Uncertainty assessment and its propagation to clonality estimates}{144}{subsection.21.3.7}%
\contentsline {subsection}{\numberline {21.3.8}Clonality of bi-allelic deletion}{144}{subsection.21.3.8}%
\contentsline {chapter}{\numberline {22}TPES: timor purity estimation from SNVs}{146}{chapter.22}%
\contentsline {section}{\numberline {22.1}Abstract}{146}{section.22.1}%
\contentsline {subsection}{\numberline {22.1.1}Introduction}{146}{subsection.22.1.1}%
\contentsline {section}{\numberline {22.2}Materials and methods}{146}{section.22.2}%
\contentsline {chapter}{\numberline {23}SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines}{148}{chapter.23}%
\contentsline {section}{\numberline {23.1}Abstract}{148}{section.23.1}%
\contentsline {subsection}{\numberline {23.1.1}Introduction}{148}{subsection.23.1.1}%
\contentsline {section}{\numberline {23.2}Material and methods}{148}{section.23.2}%
\contentsline {subsection}{\numberline {23.2.1}Genotype distance}{148}{subsection.23.2.1}%
\contentsline {subsection}{\numberline {23.2.2}SNP panel selection procedure}{149}{subsection.23.2.2}%
\contentsline {subsection}{\numberline {23.2.3}SPIA probabilistic test on cell line genotype distance}{149}{subsection.23.2.3}%
